Phase 3Active, not recruiting
Lenvatinib/Everolimus or Lenvatinib/Pembrolizumab Versus Sunitinib Alone as Treatment of Advanced Renal Cell Carcinoma (CLEAR)
A Multicenter, Open-label, Randomized, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib in Combination With Everolimus or Pembrolizumab Versus Sunitinib Alone in First-Line Treatment of Subjects With Advanced Renal Cell Carcinoma (CLEAR)
- Sponsor
- Eisai Inc. (Industry)
- Enrollment
- 1,069 enrolled
- Conditions
- Renal Cell Carcinoma
- Interventions
- Lenvatinib; Everolimus; Pembrolizumab; Sunitinib
- Ages
- adults, older adults
- Registry
- NCT02811861, EUCTR2016-000916-14
Full record on ClinicalTrials.gov
From the registry
The primary purpose of the study is to demonstrate that lenvatinib in combination with everolimus (Arm A) or pembrolizumab (Arm B) is superior compared to sunitinib alone (Arm C) in improving progression-free survival (PFS) (by independent imaging review \[IIR\] using Response Evaluation Criteria in Solid Tumors \[RECIST 1.1\]) as first-line treatment in participants with advanced renal cell carcinoma (RCC).
Primary outcomes
- Progression-free Survival (PFS) by Independent Imaging Review (IIR)
History
Study completion expected
Last registry update
Results first posted
Primary completion
Started
Registered